| Literature DB >> 32320443 |
Peter Seah Keng Tok1,2, Su May Liew3, Li Ping Wong1, Asmah Razali4, Tharani Loganathan1, Karuthan Chinna5, Nurhuda Ismail6, Naim Abdul Kadir4.
Abstract
INTRODUCTION: The monitoring of tuberculosis (TB) treatment outcomes and examination of the factors affecting these outcomes are important for evaluation and feedback of the national TB control program. This study aims to assess the TB treatment outcomes among patients registered in the national TB surveillance database in Malaysia from 2014 until 2017 and identify factors associated with unsuccessful treatment outcomes and all-cause mortality.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32320443 PMCID: PMC7176104 DOI: 10.1371/journal.pone.0231986
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Sociodemographic characteristics of the study population (n = 97,505).
| Characteristics | ||
|---|---|---|
| Below 5 years old | 1,049 (1.1) | |
| 5 to 14 years old | 1,766 (1.8) | |
| 15 to 24 years old | 15,210 (15.6) | |
| 25 to 34 years old | 18,684 (19.2) | |
| 35 to 44 years old | 16,513 (16.9) | |
| 45 to 54 years old | 16,502 (16.9) | |
| 55 to 64 years old | 14,796 (15.2) | |
| 65 years old and above | 12,983 (13.3) | |
| Female | 34,845 (35.7) | |
| Male | 62,660 (64.3) | |
| Malaysian | 85,158 (87.3) | |
| Non-Malaysian | 12,347 (12.7) | |
| Urban | 53,392 (55.1) | |
| Rural | 43,433 (44.9) | |
| Tertiary | 12,780 (13.2) | |
| Secondary | 47,851 (49.5) | |
| Primary | 17,766 (18.4) | |
| No formal education | 18,184 (18.8) | |
TB disease profile and outcomes of the study population (n = 97,505).
| Disease profile and outcomes | ||
|---|---|---|
| Passive | 89,086 (91.4) | |
| Active or screening | 8,419 (8.6) | |
| Yes | 79,699 (81.7) | |
| No | 17,806 (18.3) | |
| No | 79,954 (82.0) | |
| Yes | 17,551 (18.0) | |
| No | 66,222 (67.9) | |
| Yes | 31,283 (32.1) | |
| Pulmonary TB | 84,814 (87.0) | |
| Extrapulmonary TB | 12,691 (13.0) | |
| New case | 90,225 (92.5) | |
| Relapse case | 4,838 (5.0) | |
| Treatment after failure | 208 (0.2) | |
| Treatment after loss to follow-up | 2,234 (2.3) | |
| Positive | 61,797 (65.9) | |
| Negative | 31,935 (34.1) | |
| No lesion | 10,850 (11.3) | |
| Minimal | 48,359 (50.6) | |
| Moderately advanced | 32,593 (34.1) | |
| Far advanced | 3,815 (4.0) | |
| Negative | 87,161 (94.0) | |
| Positive | 5,603 (6.0) | |
| Cured | 48,682 (49.9) | |
| Treatment completed | 30,018 (30.8) | |
| Treatment failed | 145 (0.1) | |
| Died | 9,963 (10.2) | |
| Loss to follow-up | 5,161 (5.3) | |
| Not evaluated | 3,536 (3.6) | |
| Favorable | 78,700 (80.7) | |
| Unfavorable | 18,805 (19.3) | |
TB, tuberculosis; BCG, bacille Calmette-Guerin; HIV, human immunodeficiency virus.
Univariable and multivariable analysis for unsuccessful treatment outcomes.
| Variables | Unsuccessful outcomes | Univariate OR (95% CI) | Multivariate ( | |||
|---|---|---|---|---|---|---|
| Mean difference ± SE | 3.586 ± 0.147 | 1.011 (1.010, 1.012) | <0.001 | 1.015 (1.014, 1.016) | <0.001 | |
| Female | 4,837 (13.9) | 1 | 1 | |||
| Male | 13,968 (22.3) | 1.78 (1.72, 1.84) | <0.001 | 1.47 (1.41, 1.53) | <0.001 | |
| Malaysian | 14,310 (16.8) | 1 | 1 | |||
| Non-Malaysian | 4,495 (36.4) | 2.83 (2.72, 2.95) | <0.001 | 2.94 (2.77, 3.12) | <0.001 | |
| Urban | 10,660 (20.0) | 1.11 (1.07, 1.14) | <0.001 | 1.21 (1.17, 1.26) | <0.001 | |
| Rural | 7,992 (18.4) | 1 | 1 | |||
| Tertiary | 1,217 (9.5) | 1 | 1 | |||
| Secondary | 8,350 (17.5) | 2.01 (1.89, 2.14) | <0.001 | 1.67 (1.56, 1.79) | <0.001 | |
| Primary | 3,809 (21.4) | 2.59 (2.42, 2.78) | <0.001 | 1.81 (1.67, 1.95) | <0.001 | |
| No formal education | 5,078 (27.9) | 3.68 (3.44, 3.94) | <0.001 | 2.04 (1.89, 2.20) | <0.001 | |
| Passive | 17,317 (19.4) | 1.12 (1.06, 1.19) | <0.001 | 1.15 (1.08, 1.22) | <0.001 | |
| Active or screening | 1,488 (17.7) | 1 | 1 | |||
| Yes | 13,380 (16.8) | 1 | 1 | |||
| No | 5,425 (30.5) | 2.17 (2.09, 2.25) | <0.001 | 1.21 (1.15, 1.27) | <0.001 | |
| No | 15,383 (19.2) | 1 | 1 | |||
| Yes | 3,422 (19.5) | 1.02 (0.98, 1.06) | 0.433 | 1.08 (1.03, 1.13) | 0.002 | |
| No | 11,530 (17.4) | 1 | 1 | |||
| Yes | 7,275 (23.3) | 1.44 (1.39, 1.49) | <0.001 | 1.08 (1.04, 1.13) | <0.001 | |
| Pulmonary TB | 16,467 (19.4) | 1 | 1 | |||
| Extrapulmonary TB | 2,338 (18.4) | 0.94 (0.89, 0.98) | 0.008 | 1.31 (1.22, 1.41) | <0.001 | |
| New case | 16,735 (18.5) | 1 | 1 | |||
| Relapse case | 1,107 (22.9) | 1.30 (1.22, 1.40) | <0.001 | 1.17 (1.09, 1.26) | <0.001 | |
| Treatment after failure | 69 (33.2) | 2.18 (1.63, 2.91) | <0.001 | 2.17 (1.60, 2.94) | <0.001 | |
| Treatment after loss to follow-up | 894 (40.0) | 2.93 (2.69, 3.19) | <0.001 | 2.85 (2.60, 3.12) | <0.001 | |
| Positive | 12,091 (19.6) | 1 | 1 | |||
| Negative | 5,951 (18.6) | 0.94 (0.91, 0.98) | 0.001 | 1.00 (0.96, 1.04) | 0.959 | |
| No lesion | 1,765 (16.3) | 1 | 1 | |||
| Minimal | 8,061 (16.7) | 1.03 (0.97, 1.09) | 0.309 | 1.06 (0.99, 1.15) | 0.103 | |
| Moderately advanced | 7,286 (22.4) | 1.48 (1.40, 1.57) | <0.001 | 1.45 (1.34, 1.56) | <0.001 | |
| Far advanced | 1,340 (35.1) | 2.79 (2.56, 3.03) | <0.001 | 2.68 (2.42, 2.96) | <0.001 | |
| Negative | 14,707 (16.9) | 1 | 1 | |||
| Positive | 2,426 (43.3) | 3.76 (3.56, 3.98) | <0.001 | 4.26 (4.01, 4.53) | <0.001 | |
OR, odds ratio; AOR, adjusted odds ratio; SE, standard error (of the mean difference); TB, tuberculosis; BCG, bacille Calmette-Guerin; HIV, human immunodeficiency virus.
Univariable and multivariable analysis for all-cause mortality.
| Variables | Unsuccessful outcomes | Univariate OR (95% CI) | Multivariate ( | |||
|---|---|---|---|---|---|---|
| Mean difference ± SE | 12.190 ± 0.188 | 1.039 (1.037, 1.040) | <0.001 | 1.042 (1.040, 1.043) | <0.001 | |
| Female | 2,730 (7.8) | 1 | 1 | |||
| Male | 7,233 (11.5) | 1.54 (1.47, 1.61) | <0.001 | 1.12 (1.06, 1.19) | <0.001 | |
| Malaysian | 9,130 (10.7) | 1.66 (1.54, 1.79) | <0.001 | 1.15 (1.04, 1.26) | 0.005 | |
| Non-Malaysian | 833 (6.7) | 1 | 1 | |||
| Urban | 4,919 (9.2) | 1 | 1 | |||
| Rural | 4,976 (11.5) | 1.28 (1.22, 1.33) | <0.001 | 1.13 (1.08, 1.19) | <0.001 | |
| Tertiary | 656 (5.1) | 1 | 1 | |||
| Secondary | 4,537 (9.5) | 1.94 (1.78, 2.11) | <0.001 | 1.39 (1.27, 1.52) | <0.001 | |
| Primary | 2,440 (13.7) | 2.94 (2.69, 3.22) | <0.001 | 1.50 (1.36, 1.65) | <0.001 | |
| No formal education | 2,254 (12.4) | 2.62 (2.39, 2.86) | <0.001 | 1.73 (1.56, 1.91) | <0.001 | |
| Passive | 9,217 (10.3) | 1.19 (1.10, 1.28) | <0.001 | 1.21 (1.11, 1.32) | <0.001 | |
| Active or screening | 746 (8.9) | 1 | 1 | |||
| Yes | 7,793 (9.8) | 1 | 1 | |||
| No | 2,170 (12.2) | 1.28 (1.22, 1.35) | <0.001 | 1.07 (1.00, 1.14) | 0.037 | |
| No | 7,499 (9.4) | 1 | 1 | |||
| Yes | 2,464 (14.0) | 1.58 (1.50, 1.66) | <0.001 | 1.22 (1.15, 1.28) | <0.001 | |
| No | 6,313 (9.5) | 1 | 1 | |||
| Yes | 3,650 (11.7) | 1.25 (1.20, 1.31) | <0.001 | 0.97 (0.92, 1.02) | 0.190 | |
| Pulmonary TB | 8,658 (10.2) | 1 | 1 | |||
| Extrapulmonary TB | 1,305 (10.3) | 1.01 (0.95, 1.07) | 0.796 | 1.47 (1.34, 1.61) | <0.001 | |
| New case | 8,997 (10.0) | 1 | 1 | |||
| Relapse case | 675 (14.0) | 1.46 (1.35, 1.59) | <0.001 | 1.04 (0.95, 1.14) | 0.404 | |
| Treatment after failure | 24 (11.5) | 1.18 (0.77, 1.80) | 0.452 | 1.10 (0.70, 1.72) | 0.684 | |
| Treatment after loss to follow-up | 267 (12.0) | 1.23 (1.08, 1.40) | 0.002 | 1.08 (0.94, 1.24) | 0.271 | |
| Positive | 6,191 (10.0) | 1 | 1 | |||
| Negative | 3,347 (10.5) | 1.05 (1.01, 1.10) | 0.026 | 1.04 (0.99, 1.10) | 0.133 | |
| No lesion | 930 (8.6) | 1 | 1 | |||
| Minimal | 3,822 (7.9) | 0.92 (0.85, 0.99) | 0.021 | 1.05 (0.95, 1.16) | 0.332 | |
| Moderately advanced | 4,087 (12.5) | 1.53 (1.42, 1.65) | <0.001 | 1.75 (1.58, 1.94) | <0.001 | |
| Far advanced | 949 (24.9) | 3.53 (3.20, 3.90) | <0.001 | 4.50 (3.98, 5.10) | <0.001 | |
| Negative | 7,426 (8.5) | 1 | 1 | |||
| Positive | 1,748 (31.2) | 4.87 (4.58, 5.18) | <0.001 | 7.47 (6.97, 8.00) | <0.001 | |
OR, odds ratio; AOR, adjusted odds ratio; SE, standard error (of the mean difference); TB, tuberculosis; BCG, bacille Calmette-Guerin; HIV, human immunodeficiency virus.